Anti-human il-15 antibody and use thereof

By developing antibodies with specific HCDR and LCDR amino acid sequences, binding to IL-15 and inhibiting its activity, the problem of difficulty in effectively treating vitiligo in the prior art has been solved, and the potential therapeutic effect on IL-15-mediated diseases has been achieved.

WO2024230179A1PCT designated stage expired Publication Date: 2024-11-14BEIJING WISDOMAB BIOTECHNOLOGY CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/140302
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-05
Filing Date
2023-12-20
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing drugs for treating vitiligo are difficult to effectively target IL-15-mediated diseases, especially because IL-15 maintains survival of TRm cells and activates downstream signaling pathways, leading to disease recurrence and enhanced inflammation.

Method used

An antibody binding to human IL-15 has been developed, containing specific HCDR and LCDR amino acid sequences, capable of specifically binding to IL-15, inhibiting its activity, thereby blocking IL-15-mediated signaling pathways for prevention or treatment IL-15-mediated diseases such as vitiligo.

Benefits of technology

By blocking the IL-15 signaling pathway, inhibiting the survival and secretion of TRm cells and reducing inflammatory response, it has great potential and has significant effects in the treatment of vitiligo and other IL-15-mediated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023140302-FTAPPB-I100001
    Figure PCTCN2023140302-FTAPPB-I100001
  • Figure PCTCN2023140302-FTAPPB-I100002
    Figure PCTCN2023140302-FTAPPB-I100002
  • Figure PCTCN2023140302-FTAPPB-I100003
    Figure PCTCN2023140302-FTAPPB-I100003
Patent Text Reader

Abstract

Disclosed are an antibody binding to human IL-15, a nucleic acid molecule encoding the antibody, a vector comprising the nucleic acid molecule, a host cell comprising the nucleic acid molecule or the vector, a method for preparing and purifying the antibody and the use of the antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Antibodies against human IL-15 and uses thereof CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Chinese Patent Application No. 202310498953.4 filed on May 5, 2023, the entire contents of which are incorporated herein by reference in their entirety. Technical Field The present application generally relates to the fields of genetic engineering and antibody drugs; in particular, to antibodies binding to human IL-15 and uses thereof. Background Art The IL-15 gene is located on human chromosome 4q31 and consists of nine exons (1-8 and 4A) and eight introns, of which four exons (5 to 8) encode mature proteins. The expression of IL-15 protein is limited and strictly regulated during transcription and translation. It is mainly expressed in monocytes / macrophages and dendritic cells. [1] IL-15 is a four-alpha helical bundle cytokine. The IL-15 receptor is composed of IL-15Rα, IL-2Rβ and γc. IL-15Rα is unique to IL-15, IL-2Rβ is a co-receptor for IL-2 and IL-15, and γc (CD132) is a co-receptor for many cytokines including IL-2, IL-4, IL-7, IL-9 and IL-21. IL-15Rα binds to IL-15 to form a high-affinity stable complex, which is then presented to IL-2Rβ and γc on activated T cells or NK cells to form a high-affinity immune synapse. [2] Due to the shared receptor subunits (IL-2Rβ and γc), IL-2 and IL-15 trigger several similar downstream signaling pathways, including Janus kinase (JAK) signal transduction proteins and transcription activator proteins (STAT), exerting physiological functions of proliferation and inhibiting apoptosis. Vitiligo is a chronic autoimmune disease characterized by skin depigmentation and the appearance of white patches of various shapes and sizes on the skin or mucous membranes. This is caused by the loss and destruction of pigment-producing cells - melanocytes, which affects beauty. Vitiligo affects approximately 0.5%-2.0% of the world's population, with no significant difference between the sexes, and different incidence rates in different geographical regions. Vitiligo is divided into segmental vitiligo, non-segmental vitiligo, and mixed types. Among them, non-segmental vitiligo accounts for approximately 87% of young people under the age of 30, and is bilaterally symmetrical and distributed throughout the body. [3] . JM Richmond's research group found that there is a CD8 + Memory tissue-resident T cells TRm, after formation, can stay in the tissue for at least half a year and increase in an inflammatory environment. Biopsy of the lesioned skin of vitiligo patients confirmed the presence of a large number of active TRm in the lesioned tissue. [4]. Vitiligo often recurs in the same location, suggesting that TRm plays an important role in the progression of the disease. IL-15 is a cytokine necessary for maintaining the long-term survival of TRm. IL-15 binds to receptors on the surface of TRm cells, maintains TRm survival and stimulates TRm to secrete IFN-γ / granzyme / perforin, killing melanocytes. At the same time, IFN-γ can also activate the downstream JAK-STAT pathway, causing skin keratinocytes to secrete CXCL9 and CXCL10, recruiting more melanocyte-specific CD8 + T cells, which increase inflammation through a positive feedback loop [5] IL-15 is a potential new target for the treatment of vitiligo. Therefore, the development of functional antibodies against IL-15 is of great significance for the treatment of IL-15-mediated diseases. SUMMARY OF THE INVENTION In a first aspect, the present application provides an antibody that binds to human IL-15, comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 amino acid sequences and a light chain variable region comprising LCDR1, LCDR2 and LCDR3 amino acid sequences, wherein The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:28, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:34, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:35, and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:36; The amino acid sequence of the HCDR1 is shown in SEQ ID NO: 26, and the amino acid sequence of the HCDR2 is shown in SEQ ID NO: ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:29, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:37, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:38 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:39; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:30, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:37, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:38 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:39; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:31, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:32, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:33, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:40, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:41, and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:42; or The amino acid sequence of the HCDR1 is shown in SEQ ID NO:31, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:45, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:46, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:47, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:48 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:49; The amino acid sequences of HCDR and LCDR are based on the Kabat definition. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:13, 19, 21, 22 or 43. In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:14, 20, 23 or 44. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 14; The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 19, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 20; The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 21, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 20; The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 22, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 23; or The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:43, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:44. In a second aspect, the present application provides an antibody that binds to human IL-15, wherein the amino acid sequence of the heavy chain variable region of the antibody is at least 90% identical to any one of SEQ ID NOs: 13, 19, 21, 22 and 43, and the amino acid sequence of the light chain variable region of the antibody is at least 90% identical to any one of SEQ ID NOs: 14, 20, 23 and 44. In some embodiments of the first and second aspects, the antibody is a whole antibody, a Fab fragment, a F(ab') 2 fragment or single-chain Fv fragment (scFv); and / or The antibody is a monoclonal antibody; and / or The antibody further comprises a heavy chain constant region selected from the IgG1 subtype, IgG2 subtype or IgG4 subtype; and / or The amino acids at positions 234, 235 and 331 of the Fc fragment are F, E and S respectively; and / or The amino acids at positions 252, 254 and 256 of the heavy chain constant region are Y, T and E, respectively; and / or The antibody further comprises a light chain constant region selected from the κ subtype or the λ subtype; The amino acid positions in the antibody constant region are determined according to EU numbering. In some embodiments of the first aspect and the second aspect, the antibody binds to human IL-15 and / or monkey IL-15; and / or the antibody is capable of inhibiting the activity of IL-15. In a third aspect, the present application provides a nucleic acid molecule encoding the antibody described in the first aspect or the second aspect. In a fourth aspect, the present application provides a pharmaceutical composition comprising the antibody described in the first aspect or the second aspect and a pharmaceutically acceptable excipient, diluent or carrier. In a fifth aspect, the present application provides use of the antibody described in the first aspect or the second aspect, or the pharmaceutical composition described in the fourth aspect, in the preparation of a medicament for preventing or treating an IL-15-mediated disease. In a sixth aspect, the present application provides a method for preventing or treating an IL-15-mediated disease, comprising administering the antibody of the first aspect or the second aspect, or the pharmaceutical composition of the fourth aspect to an individual in need thereof. BRIEF DESCRIPTION OF THE DRAWINGS FIG1 shows the binding ability of anti-human IL-15 monoclonal antibodies to IL-15 from different species. Figure 2 shows the results of epitope analysis of anti-human IL-15 monoclonal antibodies. Figure 2A shows the results of anti-human IL-15 monoclonal antibodies blocking the binding of AMG714 purified phage and human IL-15; Figure 2B shows the results of anti-human IL-15 monoclonal antibodies blocking the binding of CALY-002 purified phage and human IL-15. FIG3 shows the activity results of anti-human IL-15 monoclonal antibody on HEK-blue IL-2 cells. FIG. 4 shows the activity results of anti-human IL-15 monoclonal antibodies on NK-92 cells. Sequence Description SEQ ID NO: 1 shows the amino acid sequence of the extracellular region of human (homo sapiens) IL-15 (hIL-15). SEQ ID NO: 2 shows the amino acid sequence of the extracellular region of human (homo sapiens) IL-15Ra (hIL-15Ra). SEQ ID NO: 3 shows the amino acid sequence of the extracellular region of cynomolgus monkey (Macaca fascicularis) IL-15 (mfIL-15). SEQ ID NO: 4 shows the amino acid sequence of the Macaca fascicularis IL-15Ra extracellular region (mfIL-15Ra). SEQ ID NO:5 shows the amino acid sequence of the extracellular region of murine (Mus musculus) IL-15 (mIL-15). SEQ ID NO:6 shows the amino acid sequence of the extracellular region of murine (Mus musculus) IL-15Ra (mIL-15Ra). SEQ ID NO: 7 shows the amino acid sequence of the His tag (His). SEQ ID NO: 8 shows the amino acid sequence of the Fc fragment of murine antibody IgG1 (mFc1). SEQ ID NO: 9 shows the amino acid sequence of the heavy chain constant region of homo sapiens IgG1 subtype. SEQ ID NO: 10 shows the amino acid sequence of the heavy chain constant region of human IgG1m3 subtype. SEQ ID NO: 11 shows the amino acid sequence of the human (homo sapiens) kappa subtype light chain constant region. SEQ ID NO: 12 shows the amino acid sequence of the human (homo sapiens) lambda subtype light chain constant region. SEQ ID NO: 13 shows the amino acid sequence of the heavy chain variable region R1A3VH of the anti-human IL-15 monoclonal antibody R1A3. SEQ ID NO: 14 shows the amino acid sequence of the light chain variable region R1A3VK of the anti-human IL-15 monoclonal antibody R1A3. SEQ ID NO: 15 shows the amino acid sequence of the heavy chain variable region of the anti-human IL-15 monoclonal antibody AMG714. SEQ ID NO: 16 shows the amino acid sequence of the light chain variable region of the anti-human IL-15 monoclonal antibody AMG714. SEQ ID NO: 17 shows the amino acid sequence of the heavy chain variable region of the anti-human IL-15 monoclonal antibody CALY-002. SEQ ID NO: 18 shows the amino acid sequence of the light chain variable region of the anti-human IL-15 monoclonal antibody CALY-002. SEQ ID NO: 19 shows the amino acid sequence of the heavy chain variable region R4G4VH of the anti-human IL-15 monoclonal antibody R4G4VH+R22F11VK. SEQ ID NO: 20 shows the amino acid sequence of the light chain variable region R22F11VK of the anti-human IL-15 monoclonal antibodies R4G4VH+R22F11VK and R2H2VH+R22F11VK. SEQ ID NO: 21 shows the amino acid sequence of the heavy chain variable region R2H2VH of the anti-human IL-15 monoclonal antibody R2H2VH+R22F11VK. SEQ ID NO: 22 shows the amino acid sequence of the heavy chain variable region R26H10VH of the anti-human IL-15 monoclonal antibody R26H10. acid sequence. SEQ ID NO: 23 shows the amino acid sequence of the light chain variable region R26H10VK of the anti-human IL-15 monoclonal antibody R26H10. SEQ ID NO: 24 shows the nucleotide sequence of primer PmCGR. SEQ ID NO: 25 shows the nucleotide sequence of primer PmCKR. SEQ ID NO: 26 shows the amino acid sequence of HCDR1 of heavy chain variable regions R1A3VH, R4G4VH and R2H2VH. SEQ ID NO: 27 shows the amino acid sequence of HCDR2 of heavy chain variable regions R1A3VH, R4G4VH and R2H2VH. SEQ ID NO: 28 shows the amino acid sequence of HCDR3 of the heavy chain variable region R1A3VH. SEQ ID NO: 29 shows the amino acid sequence of HCDR3 of the heavy chain variable region R4G4VH. SEQ ID NO: 30 shows the amino acid sequence of HCDR3 of the heavy chain variable region R2H2VH. SEQ ID NO: 31 shows the amino acid sequence of HCDR1 of the heavy chain variable regions R26H10VH and R6E11VH. SEQ ID NOs: 32-33 show the amino acid sequences of HCDR2 and HCDR3 of the heavy chain variable region R26H10VH, respectively. SEQ ID NOs: 34-36 show the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region R1A3VK, respectively. SEQ ID NOs: 37-39 respectively show the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region R22F11VK. SEQ ID NOs: 40-42 respectively show the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region R26H10VK. SEQ ID NO: 43 shows the amino acid sequence of the heavy chain variable region R6E11VH of the anti-human IL-15 monoclonal antibody R6E11. SEQ ID NO: 44 shows the amino acid sequence of the light chain variable region R6E11VK of the anti-human IL-15 monoclonal antibody R6E11. SEQ ID NOs: 45-46 show the amino acid sequences of HCDR2 and HCDR3 of the heavy chain variable region R6E11 VH, respectively. SEQ ID NOs: 47-49 show the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region R6E11VK, respectively. SEQ ID NO: 50 shows the amino acid sequence of the heavy chain variable region of the DP47 antibody. SEQ ID NO:51 shows the amino acid sequence of the light chain variable region of the DP47 antibody. DETAILED DESCRIPTION OF THE INVENTION The inventors of the present application have obtained new anti-human IL-15 antibodies through antibody engineering technology. In various aspects of the present application, new anti-human IL-15 antibodies, nucleic acid molecules encoding the antibodies, vectors containing the nucleic acid molecules, host cells containing the nucleic acid molecules or vectors, methods for preparing and purifying the antibodies, and medical and biological applications of the antibodies are provided. According to the amino acid sequence of the variable region of the antibody provided in the present application, a full-length antibody molecule can be constructed as a drug for preventing or treating human IL-15-mediated diseases. The practice of the present application employs, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology, biochemistry, and immunology within the skill of the art. Unless otherwise specified, the terms used in this application have the meanings commonly understood by those skilled in the art. definition As used herein, the term "antibody" refers to an immunoglobulin molecule that is capable of specifically binding to a target via at least one antigen recognition site located in the variable region of the immunoglobulin molecule. Targets include, but are not limited to, carbohydrates, Polynucleotides, lipids, polypeptides, etc. As used herein, "antibodies" include not only intact (i.e., full-length) antibodies, but also antigen-binding fragments thereof (e.g., Fab, Fab', F(ab') 2 , Fv), its variants, fusion proteins comprising antibody portions, humanized antibodies, chimeric antibodies, diabodies, linear antibodies, single-chain antibodies, multispecific antibodies (e.g., bispecific antibodies), and any other modified configurations of immunoglobulin molecules comprising an antigen recognition site of desired specificity, including antibody glycosylation variants, antibody amino acid sequence variants, and covalently modified antibodies. Typically, a complete or full-length antibody comprises two heavy chains and two light chains. Each heavy chain contains a heavy chain variable region (VH) and the first, second and third constant regions (CH1, CH2 and CH3). Each light chain contains a light chain variable region (VL) and a constant region (CL). A full-length antibody can be any type of antibody, such as IgD, IgE, IgG, IgA or IgM (or subclasses thereof), but the antibody need not belong to any particular class. Immunoglobulins can be assigned to different classes based on the antibody amino acid sequence of the heavy chain constant domain. Typically, there are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these classes can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy chain constant domains corresponding to different classes of immunoglobulins are referred to as α, δ, ε, γ, and μ, respectively. The subunit structure and three-dimensional structure of different classes of immunoglobulins are well known. As used herein, the term "antigen binding fragment or antigen binding portion" refers to a portion or region of a complete antibody molecule that is responsible for binding to an antigen. The antigen binding domain may comprise a heavy chain variable region (VH), a light chain variable region (VL), or both. Each of VH and VL typically contains three complementary determining regions, CDR1, CDR2, and CDR3. It is well known to those skilled in the art that the complementarity determining region (CDR, usually CDR1, CDR2 and CDR3) is the region in the variable region that has the greatest impact on the affinity and specificity of the antibody. There are two common definitions of the CDR amino acid sequence of VH or VL, namely the Chothia definition and the Kabat definition. See, for example, Kabat, "Sequences of Proteins of Immunological Interest", National Institutes of Health, Bethesda, Md. (1991) 7 ; Al-Lazikani et al., J. Mol. Biol. 273:927-948 (1997) 8 ; and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989) 9 For the variable region amino acid sequence of a given antibody, the CDR amino acid sequence in the VH and VL amino acid sequences can be determined according to the Chothia definition or the Kabat definition. In the embodiments of the present application, the Kabat definition of the CDR amino acid sequence is used. For a given antibody variable region amino acid sequence, the CDR amino acid sequence in the variable region amino acid sequence can be analyzed in a variety of ways, for example, it can be determined using the online software Abysis (http: / / www.abysis.org / ). Examples of antigen-binding fragments include, but are not limited to: (1) Fab fragments, which can be monovalent fragments having a VL-CL chain and a VH-CH1 chain; (2) F(ab') 2 (i) a bivalent fragment having two Fab' fragments connected by a disulfide bridge at the hinge region (i.e., a dimer of Fab'); (ii) an Fv fragment having the VL and VH domains of a single arm of an antibody; (iii) a single-chain Fv (scFv), which can be a single polypeptide chain consisting of a VH domain and a VL domain via a peptide linker; and (iv) (scFv) 2 , which may comprise two VH domains connected by a peptide linker and two VL domains, the two VL domains being combined with the two VH domains via a disulfide bridge. As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the binding of an antibody to an antigen epitope. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, ie, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may occur in minor individuals. As used herein, the term "humanized antibody" refers to an antibody whose constant region (i.e., CH and CL regions) or all of the antibody is encoded by human antibody genes. Humanized antibodies can greatly reduce the immune side effects caused by heterologous antibodies to the human body. Humanized antibodies include chimeric antibodies, modified antibodies, and fully humanized antibodies. In a first aspect, the present application provides an antibody that binds to human IL-15, comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 amino acid sequences and a light chain variable region comprising LCDR1, LCDR2 and LCDR3 amino acid sequences, wherein The amino acid sequence of the HCDR1 is shown in SEQ ID NO: 26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO: 27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO: 28, and the amino acid sequence of the LCDR1 is shown in SEQ ID NO: The sequence is shown in SEQ ID NO:34, the amino acid sequence of LCDR2 is shown in SEQ ID NO:35, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:36; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:29, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:37, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:38 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:39; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:30, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:37, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:38 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:39; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:31, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:32, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:33, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:40, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:41, and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:42; or The amino acid sequence of the HCDR1 is shown in SEQ ID NO:31, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:45, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:46, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:47, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:48 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:49; The amino acid sequences of HCDR and LCDR are based on the Kabat definition. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:13. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:19. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:21. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:22. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:43. In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:14. In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:20. In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:23. In some embodiments of the first aspect, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:44. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:13, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:14. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:19, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:20. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:21, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:20. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is as shown in SEQ ID NO: 22 As shown, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:23. In some embodiments of the first aspect, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:43, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:44. In a second aspect, the present application provides an antibody that binds to human IL-15, wherein the amino acid sequence of the heavy chain variable region of the antibody is at least 90% identical to any one of SEQ ID NOs: 13, 19, 21, 22 and 43, and the amino acid sequence of the light chain variable region of the antibody is at least 90% identical to any one of SEQ ID NOs: 14, 20, 23 and 44. In some embodiments of the second aspect, the amino acid sequence of the heavy chain variable region of the antibody is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of SEQ ID NOs: 13, 19, 21, 22 and 43. In some embodiments of the second aspect, the amino acid sequence of the light chain variable region of the antibody is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to any one of SEQ ID NOs: 14, 20, 23 and 44. In some embodiments of the second aspect, the amino acid sequence of the heavy chain variable region of the antibody differs from the amino acid sequence shown in any one of SEQ ID NOs: 13, 19, 21, 22 and 43 by about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, deletions and / or additions. In some embodiments of the second aspect, the amino acid sequence of the light chain variable region of the antibody differs from the amino acid sequence shown in any one of SEQ ID NOs: 14, 20, 23 and 44 by about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, deletions and / or additions. In some embodiments of the second aspect, the C-terminal or N-terminal region of the amino acid sequence shown in any one of SEQ ID NOs: 13, 19, 21, 22 and 43 can also be truncated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids, while still maintaining similar function of the heavy chain variable region of the antibody. In some embodiments of the second aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids can be added to the C-terminal or N-terminal region of the amino acid sequence shown in any one of SEQ ID NOs: 13, 19, 21, 22 and 43, and the resulting amino acid sequence still maintains the function of the heavy chain variable region of the similar antibody. In some embodiments of the second aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added or deleted in the region other than the C-terminus or N-terminus of the amino acid sequence shown in any one of SEQ ID NOs: 13, 19, 21, 22 and 43, as long as the altered amino acid sequence substantially maintains the function of the heavy chain variable region of the similar antibody. In some embodiments of the second aspect, the C-terminal or N-terminal region of the amino acid sequence shown in any one of SEQ ID NOs: 14, 20, 23 and 44 can also be truncated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids, while still maintaining similar function of the light chain variable region of the antibody. In some embodiments of the second aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids can be added to the C-terminal or N-terminal region of the amino acid sequence shown in any one of SEQ ID NOs: 14, 20, 23 and 44, and the resulting amino acid sequence still maintains the function of the light chain variable region of the similar antibody. In some embodiments of the second aspect, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25 or more amino acids may be added or deleted in the region other than the C-terminus or N-terminus of the amino acid sequence shown in any one of SEQ ID NOs: 14, 20, 23 and 44, as long as the altered amino acid sequence substantially maintains the function of the light chain variable region of the similar antibody. In some embodiments of the first and second aspects, the antibody is a whole antibody, a Fab fragment, a F(ab') 2 Fragment or single-chain Fv fragment (scFv). In some embodiments of the first and second aspects, the antibody is a fully human antibody or a humanized antibody. In some embodiments of the first and second aspects, the antibody is a monoclonal antibody. In some embodiments of the first and second aspects, the antibody further comprises a heavy chain constant region selected from the IgG1 subtype, IgG2 subtype, or IgG4 subtype. In some specific embodiments of the first and second aspects, the heavy chain constant region is of IgG1 subtype, such as IgG1m3 subtype. In some embodiments of the first aspect and the second aspect, the amino acids at positions 234, 235 and 331 of the Fc fragment are F, E and S, respectively; wherein the amino acid positions of the antibody constant region are determined according to EU numbering. In some embodiments of the first aspect and the second aspect, the amino acids at positions 252, 254 and 256 of the heavy chain constant region are Y, T and E, respectively; wherein the amino acid positions of the antibody constant region are determined according to EU numbering. In some embodiments of the first and second aspects, the antibody further comprises a light chain constant region selected from the κ subtype or the λ subtype. In some specific embodiments of the first and second aspects, the antibody further comprises a light chain constant region selected from the κ subtype. In some embodiments of the first and second aspects, the antibody binds human IL-15. In some specific embodiments of the first and second aspects, the antibody binds to recombinant human IL-15 (SEQ ID NO: 1). In some embodiments of the first and second aspects, the antibody binds monkey IL-15. In some specific embodiments of the first and second aspects, the antibody binds to recombinant monkey IL-15 (SEQ ID NO: 3). In some embodiments of the first and second aspects, the antibody binds to a complex of IL-15 and IL-15α, such as a complex of human IL-15 and human IL-15α, or a complex of monkey IL-15 and monkey IL-15α. In some embodiments of the first and second aspects, the antibody is capable of inhibiting the activity of IL-15. In some specific embodiments of the first and second aspects, the antibody inhibits the ability of IL-15 to induce the secretion of secretory embryonic alkaline phosphatase (SEAP). In some specific embodiments of the first and second aspects, the antibody inhibits the ability of IL-15 to induce proliferation of NK92 cells. In some embodiments of the first and second aspects, the antibody does not bind to murine IL-15, eg, recombinant murine IL-15 (SEQ ID NO: 5). In a third aspect, the present application provides a nucleic acid molecule encoding the antibody described in the first aspect or the second aspect. In some embodiments of the third aspect, the nucleic acid molecule may include a DNA molecule and an RNA molecule. The nucleic acid molecule may be single-stranded or double-stranded, and may be a cDNA. In some embodiments of the third aspect, the nucleic acid molecule is operably linked to a regulatory amino acid sequence that can be recognized by a host cell transformed with the vector. In a fourth aspect, the present application provides a pharmaceutical composition comprising the antibody described in the first aspect or the second aspect and a pharmaceutically acceptable excipient, diluent or carrier. In some embodiments of the fourth aspect, the pharmaceutical composition is used to prevent or treat an IL-15-mediated disease. In some embodiments of the fourth aspect, the IL-15 mediated disease is selected from the group consisting of vitiligo, celiac disease, eosinophilic esophagitis, and large granular lymphocytic leukemia. In some embodiments of the fourth aspect, the pharmaceutical composition may also include one or more of the following: lubricants, such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers; suspending agents; preservatives, such as benzoic acid, sorbic acid and calcium propionate; sweeteners and / or flavoring agents, etc. In some embodiments of the fourth aspect, the pharmaceutical composition of the present application can be formulated into the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, suppositories or capsules. In some embodiments of the fourth aspect, the pharmaceutical composition of the present application can be delivered by any physiologically acceptable administration method, including but not limited to oral administration, parenteral administration, nasal administration, direct administration, Enteral administration, intraperitoneal administration, intravascular injection, subcutaneous administration, transdermal administration, inhalation administration, etc. In some embodiments of the fourth aspect, pharmaceutical compositions for therapeutic use can be formulated for storage in the form of lyophilized preparations or aqueous solutions by mixing reagents having the desired purity with pharmaceutically acceptable carriers, excipients, etc. as appropriate. In a fifth aspect, the present application provides use of the antibody described in the first aspect or the second aspect, or the pharmaceutical composition described in the fourth aspect in the preparation of a medicament for preventing or treating IL-15-mediated diseases. In some embodiments of the fifth aspect, the IL-15 mediated disease is selected from the group consisting of vitiligo, celiac disease, eosinophilic esophagitis, and large granular lymphocytic leukemia. In a sixth aspect, the present application provides a method for preventing or treating an IL-15-mediated disease, comprising administering the antibody of the first aspect or the second aspect, or the pharmaceutical composition of the fourth aspect to an individual in need thereof. In some embodiments of the sixth aspect, the IL-15 mediated disease is selected from the group consisting of vitiligo, celiac disease, eosinophilic esophagitis, and large granular lymphocytic leukemia. In other aspects, the application also provides a vector comprising the nucleic acid molecule, a host cell comprising the nucleic acid molecule or the vector, and a method for producing the antibody. In some embodiments, the method for producing the antibody comprises culturing the host cell to express the nucleic acid. In some embodiments, the method for producing the antibody also comprises recovering the antibody from the host cell culture medium. It should be understood that the above detailed description is only for the purpose of enabling those skilled in the art to more clearly understand the content of the present application, and is not intended to be limiting in any aspect. Those skilled in the art can make various modifications and changes to the embodiments. Example The following examples are for illustration purposes only and are not intended to limit the scope of this application. Example 1: Preparation of recombinant protein In the process of preparing and identifying IL-15-specific antibodies, a variety of different recombinant proteins are needed, including super agonists composed of human IL-15 (hIL15, SEQ ID NO: 1) and human IL-15Rα (hIL-15Rα, SEQ ID NO: 2), super agonists composed of monkey IL-15 (mfIL-15, SEQ ID NO: 3) and monkey IL-15Rα (mfIL-15Rα, SEQ ID NO: 4), and super agonists composed of mouse IL-15 (mIL-15, SEQ ID NO: 5) and mouse IL-15Rα (mIL-15Rα, SEQ ID NO: 6). Adding a His tag (His, SEQ ID NO: 7) or the Fc segment of mouse antibody IgG1 (mFc1, SEQ ID NO: 8) to the C-terminus of IL-15Rα is conducive to the purification and functional identification of recombinant proteins. When preparing recombinant antibodies, the antibody heavy chain constant region can be human IgG1 subtype (SEQ ID NO: 9) or various mutants of selected human IgG1 subtype, such as IgG1m3 (SEQ ID NO: 10); the light chain constant region can be human κ subtype (SEQ ID NO: 11) or human λ subtype (SEQ ID NO: 12). According to the amino acid sequence of the recombinant protein in the Uniprot database, the genes of the above-mentioned various recombinant proteins (including His or mFc1 tags) are designed and synthesized. The synthesized various recombinant protein genes are cloned into suitable eukaryotic expression vectors (such as pcDNA3.1 of Invitrogen, etc.) using conventional molecular biological techniques, and then the prepared recombinant protein expression plasmids are transfected into HEK293 cells (such as HEK293F of Invitrogen) using liposomes (such as 293fectin of Invitrogen, etc.) or other cationic transfection reagents (such as PEI, etc.), and cultured under serum-free suspension culture conditions for 3-4 days. Then the culture supernatant is harvested by centrifugation or the like. Use metal chelate affinity chromatography columns (such as GE's HisTrap FF, etc.) to purify the recombinant protein expressed by His tag fusion in the culture supernatant in one step. Use ProteinA / G affinity chromatography columns (such as GE's Mabselect SURE, etc.) to purify the recombinant protein expressed by antibody and Fc fusion in one step. Then use a desalting column (such as GE's Hitrap desaulting, etc.) to replace the recombinant protein storage buffer with PBS (pH7.0) or other suitable buffer. After filtration and sterilization, store it in aliquots at -20℃ for later use. Example 2: Screening of anti-hIL-15 monoclonal antibodies from a fully human Fab phage library 2.1 Screening of the fully human Fab library The recombinant human IL-15 + IL-15Rα superagonist prepared in Example 1 was used as an antigen, and a solid phase screening strategy was used (the experimental scheme refers to phage display: a general experimental guide, edited by Clarkson, T., Lowman, HB; translated by Ma Lan et al., Chemical Industry Press, 2008.5) [6] Screening of a fully human Fab phage library (see Chinese patent application No. 202210871809.6) [7] A total of three rounds of screening were carried out by means of binding, elution, neutralization, infection, and amplification, and finally a monoclonal antibody R1A3 that specifically binds to human IL-15 was obtained (the amino acid sequence of the heavy chain variable region R1A3VH is shown in SEQ ID NO: 13; the amino acid sequence of the light chain variable region R1A3VK is shown in SEQ ID NO: 14). R1A3 was prepared into IgG1m3 subtype full antibody by conventional molecular biological methods, and referring to U.S. Patent No. US7153507B2 [8] , synthesized the heavy chain variable region (SEQ ID NO: 15) and light chain variable region (SEQ ID NO: 16) of AMG714, and prepared the IgG1m3 subtype full antibody AMG714 for control study. Similarly, referring to US Patent No. US10301384B2 [9] , the heavy chain variable region (SEQ ID NO: 17) and light chain variable region (SEQ ID NO: 18) of CALY-002 were synthesized to prepare the IgG1m3 subtype full antibody CALY-002 for control studies. 2.2 Affinity analysis of anti-human IL-15 monoclonal antibody R1A3 The affinity of anti-IL-15 monoclonal antibody was determined by surface plasmon resonance using Biacore T200. The amino coupling kit (BR-1000-50), human antibody capture kit (BR-1008-39), S series CM5 chip (14100530) and 10×HBS-EP at pH 7.4 (BR100669) and other related reagents and consumables were purchased from GE healthcare. According to the instructions in the kit, the carboxylated CM5 chip surface was activated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), and the anti-human IgG (Fc) antibody (capture antibody) was diluted to 25 μg / mL with 10 mM sodium acetate (pH 5.0) and then injected at a flow rate of 10 μL / min to achieve a coupling amount of approximately 10,000 response units (RU). After the injection of the capture antibody, 1 M ethanolamine was injected to block unreacted groups. For kinetic measurements, the anti-IL-15 monoclonal antibody was diluted to 1 μg / mL and injected at 10 μL / min to ensure that about 200 RU of the antibody was captured by the anti-human Fc antibody. Then, a series of concentration gradients (e.g., 1.23 nM, 3.7 nM, 11.1 nM, 33.3 nM, and 100 nM) of the IL-15+IL-15Rα complex were set and injected from low to high concentrations at a flow rate of 30 μL / min, with an association time of 90 s and a dissociation time of 1200 s. 3 M MgCl was injected at a flow rate of 10 μL / min. 2 The chip surface was regenerated for a total of 30 s. The association rate (K) was calculated by fitting the association and dissociation sensorgrams with a 1:1 binding model using Biacore T200 Evaluation Software version 3.2.1. a ) and dissociation rate (K d ). With the ratio K d / K a Calculate the dissociation equilibrium constant (K D ). The fitting results are shown in Table 1. Table 1. Affinity constants of anti-human IL-15 monoclonal antibodies binding to human IL-15 (IL-15+IL-15Rα complex) Example 3: Preparation of R1A3 mutant 3.1 Preparation of R1A3 recombinant mutant library By using conventional molecular biological methods, mutations were introduced into CDR3 of the heavy chain variable region R1A3VH to construct a CDR3 mutation library based on R1A3VH. The designed mutation scheme is shown in Table 2. The constructed library capacity is 2E+7 and the accuracy is 82%. Table 2 Mutation scheme of CDR3 mutation library based on R1A3VH 3.2 Screening of R1A3 recombinant mutant library Based on the recombinant library phage display system (see Example 1 of Chinese Patent Application No. 202210871809.6), the prepared R1A3 heavy chain mutation library and the fully human light chain antibody library were recombined to construct a recombinant Fab mutation library. The recombinant human IL-15 + IL-15Rα superagonist prepared in Example 1 was used as an antigen, and the recombinant Fab mutation library prepared was screened by solid phase screening strategy (experimental protocol refers to phage display: a general experimental guide, (US) Clarkson (Clackson, T.), (US) Lowman (Lowman, HB); translated by Ma Lan et al., Chemical Industry Press, 2008.5), and a total of 3 rounds of screening were carried out by binding, elution, neutralization, infection, and amplification. Finally, the anti-human IL15 monoclonal antibodies R4G4VH + R22F11VK (the amino acid sequence of the heavy chain variable region R4G4VH is shown in SEQ ID NO: 19; the amino acid sequence of the light chain variable region R22F11VK is shown in SEQ ID NO: 20) and R2H2VH + R22F11VK (the amino acid sequence of the heavy chain variable region R2H2VH is shown in SEQ ID NO: 21; the amino acid sequence of the light chain variable region R22F11VK is shown in SEQ ID NO: 22) were obtained. NO:20 shown). 3.3 Affinity analysis of R1A3 mutants Referring to Example 2.2, the affinity of anti-human IL-15 monoclonal antibody R1A3 and its mutants was analyzed using Biacore T200. The results are shown in Table 3. Table 3. Affinity constants of anti-human IL-15 monoclonal antibody R1A3 and its mutants binding to human IL-15 (IL-15+IL-15Rα complex) Example 4: Screening of mouse anti-human IL-15 monoclonal antibodies from mouse immune library 4.1 Preparation of hIL-15 mouse immune library The recombinant proteins hIL-15+hIL-15Rα and mfIL-15+mfIL-15Rα superagonist prepared in Example 1 were used as antigens to immunize 6-8 week old BALB / c mice at an immunization dose of 50 μg / mouse. The mice were boosted once every 14 days. The mice were killed 8 weeks after the primary immunization and spleen cells were collected. Mouse spleen lymphocytes were isolated using mouse lymphocyte separation solution (Dakoway Biotechnology Co., Ltd., CAT#DKW33-R0100), and total RNA was extracted from the isolated lymphocytes using a cell total RNA extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., CAT#DP430). The extracted total RNA was used as a template, and the antibody heavy chain variable region and light chain variable region were synthesized using the first strand cDNA synthesis kit (Thermo scientific, CAT#K1621). The reverse transcription primers used gene-specific primers, and the primer pairing regions were located in the antibody heavy chain constant region and the antibody light chain constant region, respectively. The specific sequences were PmCGR:TGCATTTGAACTCCTTGCC (SEQ ID NO: 24) and PmCKR:CCATCAATCTTCCACTTGAC (SEQ ID NO: 25). The synthesized cDNA was immediately stored at -70°C for future use. Then, the cDNA obtained by reverse transcription was used as a template, and references (Krebber A, Bornhauser S, Burmester J,et al.,Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system.J Immunol Methods.1997;201(1):35-55

[0010] , the entire contents of the above document are incorporated herein by reference) and used PCR to amplify the nucleotide sequences encoding mouse antibodies VH and VK, respectively, and then cloned into recombinant plasmids pHGDisn-attP-new and pHKb-attB-new, respectively (for the preparation method of the recombinant plasmid, please refer to Example 1 of Chinese Patent Application No. 202210871809.6). The prepared PHGDisn-attP-new-mVHs heavy chain library (library capacity 6.1E+7, accuracy 63%) and PHKb-attB-new-mVKs light chain library (library capacity 7.4E+7, accuracy 78%) were recombined (see Example 1 of Chinese Patent Application No. 202210871809.6) to prepare a mouse recombinant phage library. The constructed library capacity reached 2.7E+11 and the sequencing accuracy was 60%. 4.2 Screening of hIL-15 mouse immune library The recombinant human IL-15+IL-15Rα and monkey IL-15+IL-15Rα superagonist prepared in Example 1 were used as antigens, and the prepared mouse recombinant phage library was screened using a solid phase screening strategy (the experimental protocol refers to phage display: a general experimental guide, (US) Clarkson (Clackson, T.), (US) Lowman (Lowman, HB); Ma Lan et al. Translated, Chemical Industry Press, 2008.5). A total of three rounds of screening were carried out by binding, elution, neutralization, infection, and amplification, and finally a mouse monoclonal antibody R6E11 that specifically binds to human IL-15 was obtained (the amino acid sequence of the heavy chain variable region R6E11VH is shown in SEQ ID NO: 43; the amino acid sequence of the light chain variable region R6E11VK is shown in SEQ ID NO: 44). 4.3 Affinity analysis of mouse anti-human IL-15 monoclonal antibody R6E11 Referring to Example 2.2, the affinity of the anti-IL-15 monoclonal antibody R6E11 was analyzed using Biacore T200. The results are shown in Table 4. Table 4. Affinity constants of mouse anti-human IL-15 antibody R6E11 binding to human IL-15 (IL-15+IL-15Rα complex) Example 5: Humanization of murine monoclonal antibody R6E11 5.1 Humanization of R6E11 The mouse monoclonal antibody R6E11 was humanized to reduce its immunogenicity. The humanization scheme adopted the classic framework transplantation strategy (J Immunol, 2002 Jul 15; 169(2): 1119-25)

[0011] . The heavy chain variable region and light chain variable region of R6E11 were compared with the human antibody germline gene sequences in the IMGT database, and the appropriate germline gene sequences were selected to provide the framework regions 1 to 3 (FR1+FR2+FR3) of the antibody, and the appropriate J region gene sequence was selected to provide the framework region 4 (FR4). This template can be selected based on a variety of factors, such as the relative total length of the antibody, the size of the CDR, the amino acid residues located at the junction between the antibody framework region (FR) and the hypervariable region (CDR), the homology of the entire sequence, etc. The selected template can be a mixture of multiple sequences or can be a common template, with the aim of maintaining the appropriate conformation of the parent complementarity determining region (CDR) as much as possible. Finally, a humanized heavy chain variable region mutant R6E11VH-h3 and a humanized light chain variable region mutant R6E11VK-h3 were obtained. 5.2 Screening of humanized R6E11 mutants Considering that the heavy chain sequence of the humanized mutant R6E11VH-h3+R6E11VK-h3 contains deamination sites NG and NA, mutation design was performed on R6E11VH-h3 to improve its physicochemical properties. The mutation scheme is shown in Table 5. The constructed library capacity was 2E+7, and the accuracy was 47%. Table 5 Mutation scheme based on R6E11VH-h3 mutation library Based on the recombinant library phage display system (see Example 1 of Chinese Patent Application No. 202210871809.6), the prepared R6E11VH-h3 mutation library and the fully human light chain antibody library were recombined to construct a recombinant Fab mutation library. By solid phase screening, the constructed recombinant Fab mutation library was screened and enriched for 3 rounds using human IL-15+IL-15Rα superagonist antigen, and finally the monoclonal antibody R26H10 containing a fully human light chain with improved physicochemical properties was obtained (the amino acid sequence of the heavy chain variable region R26H10VH is shown in SEQ ID NO: 22; the amino acid sequence of the light chain variable region R26H10VK is shown in SEQ ID NO: 23). 5.3 Affinity analysis of humanized R6E11 mutants Referring to Example 2.2, affinity analysis was performed on the anti-human IL-15 mouse monoclonal antibody R6E11 and its humanized mutants using Biacore T200. The results are shown in Table 6. Table 6. Affinity constants of anti-human IL-15 mouse monoclonal antibody R6E11 and its humanized mutants binding to human IL-15 (IL-15+IL-15Rα complex) Example 6: Binding and affinity analysis of anti-human IL-15 monoclonal antibodies to IL-15 of different species The prepared human IL-15 (hIL-15 + hIL-15Rα-His complex), cynomolgus monkey IL-15 (mfIL-15 + mfIL-15Rα-His complex) and mouse IL-15 (mIL-15 + mIL-15Rα-mFc1 complex) were coated on 96-well ELISA plates, 1 μg / mL, 100 μL / well, and coated overnight at 4°C. After blocking with blocking solution (3% skim milk-PBST) at 37°C for 1 hour, each anti-IL-15 monoclonal antibody was added and bound at 37°C for 1 hour. The ELISA plate was washed with PBST, and HRP mouse anti-human IgG (Beijing Bioson Biotechnology Co., Ltd., bsm-0297M-HRP) was added and bound at 37°C for 1 hour. The ELISA plate was washed with PBST, and OPD substrate colorimetric solution was added. After 5-10 minutes, 1M H 2 SO 4 The color development was stopped, and the optical density value was measured by a microplate reader at a dual wavelength of 492 nm / 630 nm. The results of ELISA analysis (Figure 1) showed that the anti-human IL-15 antibodies R1A3, R2H2VH+R22F11VK, R4G4VH+R22F11VK and R26H10 all cross-recognized human IL-15 and cynomolgus monkey IL-15, and all molecules did not recognize mouse IL-15. Referring to Example 2.2, the affinity of the anti-human IL-15 monoclonal antibody binding to human IL-15 and cynomolgus monkey IL-15 was analyzed using Biacore T200. The results are shown in Tables 7 and 8. Table 7 Affinity constants of anti-human IL-15 monoclonal antibodies binding to human IL-15 (hIL-15+hIL-15Rα complex) Table 8 Affinity constants of anti-human IL-15 monoclonal antibodies binding to cynomolgus monkey IL-15 (mfIL-15 + mfIL-15Rα complex) Example 7: Epitope Analysis of Anti-Human IL-15 Monoclonal Antibodies Human IL-15 (hIL-15 + hIL-15Rα-his complex) was coated on a 96-well ELISA plate at 1 μg / mL, 100 μL / well, and coated overnight at 4°C. Blocked with blocking solution (3% skim milk-PBST) at 37°C for 1 hour. A fixed concentration of anti-human IL-15 purified phage (4×10 11 cfu / mL, CALY-002 is 1×10 10cfu / mL) were used for gradient dilution of anti-human IL-15 monoclonal antibodies (R1A3, R2H2VH+R22F11VK, R4G4VH+R22F11VK, R26H10, AMG714 and CALY-002), with a starting concentration of 30 μg / mL, 3-fold gradient dilution, a total of 11 concentration gradients, 100 μL / well was added to the blocked 96-well ELISA plate, and incubated at 37°C for 1 hour. The ELISA plate was washed with PBST, and then HRP-labeled anti-M13 secondary antibody (Beijing Yiqiao Shenzhou Technology Co., Ltd., 11973-MM05T-H) was added and incubated at 37°C for 1 hour. The ELISA plate was washed with PBST, and OPD substrate colorimetric solution was added. After 5-10 minutes, 1M H 2 SO 4 The color development was stopped, and the dual-wavelength optical density value of 492nm / 630nm was measured using an ELISA reader. The results of ELISA analysis are shown in Figure 2. The epitope of R26H10 binding to human IL-15 is different from that of AMG714 (Figure 2A), and is similar to or overlaps with that of CALY-002 (Figure 2B); the epitopes of R1A3, R2H2VH+R22F11VK and R4G4VH+R22F11VK binding to human IL-15 are similar to or overlaps with that of AMG714 (Figure 2A), and are different from those of CALY-002 (Figure 2B); the epitope of AMG714 binding to human IL-15 is different from that of CALY-002 (Figure 2B). Example 8: Activity evaluation of anti-human IL-15 monoclonal antibody on HEK-Blue IL-2 cells HEK-Blue IL2 cells are HEK293-derived cells stably transfected with human CD25 (IL-2Rα), CD122 (IL-2Rβ) and CD132 (IL-2Rγ) genes, and IL-2 signals are realized through the JAK-STAT5 pathway. At the same time, the STAT5-induced secretory embryonic alkaline phosphatase (SEAP) reporter gene is also introduced into HEK-blue cells. Under the stimulation of IL-2 or IL-15, HEK-Blue IL-2 cells can activate JAK / STAT5 and secrete SEAP. The SEAP detection kit QUANTI-Blue TM Solution can monitor the amount of SEAP, thereby realizing the activity monitoring of IL-2 or IL-15. HEK-Blue IL-2 cell line was purchased from Invivogen. DMEM + 5% inactivated FBS was prepared as the test medium, and HEK-Blue IL-2 cells were resuspended in the test medium to 5*10 5 / mL. 5ng / mL human IL-15 (hIL-15+hIL-15Rα complex) was used as the antibody diluent. The antibody concentration gradient was 400nM starting, 4-fold dilution, and 10 concentration points. 100μL of antibody and 100μL of cells were mixed and placed in a carbon dioxide incubator (37℃, 5% CO 2 ) for 20 hours. Centrifuge and take 20 μL of supernatant, mix with 180 μL Quanti-blue (Invivogen, catalog number rep-qbs) and incubate at 37°C for 1-2 hours. Detect the absorbance at 630 nm using a microplate reader (Biotek, model 800TS). Analyze the raw data using Graphpad Prism 7.0 software. DP47 antibody (negative control, refer to US patent application US 20160200833A1

[0012] The results are shown in Figure 3. The activities of the four molecules R1A3, R4G4VH+R22F11VK, R2H2VH+R22F11VK and R26H10 were higher than those of CALY-002 and AMG-714. The specific IC 50 See Table 9 for data. Table 9 Activity of anti-human IL-15 monoclonal antibodies on HEK-Blue IL-2 cells Example 9: Activity evaluation of anti-human IL-15 monoclonal antibody on NK92 cells NK92 cell line was purchased from Nanjing Kebai Biotechnology Co., Ltd. It is a cell line that depends on IL-2 for proliferation. IL-15 can promote cell proliferation when IL-2 is starved. NK92 cells were starved one day in advance (blank culture without IL-2), and the cells were resuspended to 5*10 in medium without IL-2 on the second day. 5 / mL. 12ng / mL human IL-15 (hIL-15+hIL-15Rα-his complex) was used as the antibody diluent. The antibody concentration gradient was 400nM starting, 4-fold dilution, and 10 concentration points. 100μL of antibody and 100μL of cells were mixed and placed in a carbon dioxide incubator (37℃, 5% CO 2 ) for 2 days. Cell viability assay Luminescent Cell Viability Assay (Promega, catalog number G7571) was used to detect cell proliferation, and full-wavelength fluorescence detection was performed using an ELISA reader (Molecular Devices, model SpectraMax I3X). Graphpad Prism 7.0 software was used to perform statistical processing on the raw data. DP47 antibody was used as a negative control. The results are shown in Figure 4. The activities of the four anti-human IL-15 monoclonal antibodies R1A3, R26H10, R4G4VH+R22F11VK, and R2H2VH+R22F11VK were higher than AMG-714 and similar to CALY-002. Among them, CALY-002 could not completely inhibit the activity of IL-15 in NK92 cells. 50 See Table 10 for data. Table 10 Activity of anti-human IL-15 monoclonal antibodies on NK92 cells Sequence information References 1. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012 Jan; 33(1):35-41. 2.Fehniger TA,Caligiuri MA.Interleukin 15:biology and relevance to human disease.Blood.2001 Jan 1;97(1):14-32. 3. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021 Mar; 48(3):252-270. 4. Richmond JM, Strassner JP, Rashighi M, et al. Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. J Invest Dermatol. 2019 Apr; 139(4):769-778. 5. Richmond JM, Strassner JP, Zapata L Jr, et al.. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018 Jul 18; 10 (450). 6. Phage display: A general experimental guide / (US) Clarkson (Clackson, T.), (US) Lowman (Lowman, HB); (US) Translated by Ma Lan et al. Chemical Industry Press, 2008.5. 7.CN202210871809.6. 8.US7153507B2. 9.US10301384B2. 10. Krebber A, Bornhauser S, Burmester J, et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods. 1997; 201(1):35-55. 11.J Immunol, 2002 Jul 15;169(2):1119-25.

Claims

1. An antibody that binds to human IL-15, comprising a heavy chain variable region comprising the amino acid sequences of HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising the amino acid sequences of LCDR1, LCDR2 and LCDR3, wherein The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:29, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:37, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:38 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:39; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:28, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:34, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:35, and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:36; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:26, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:27, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:30, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:37, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:38 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:39; The amino acid sequence of the HCDR1 is shown in SEQ ID NO:31, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:32, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:33, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:40, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:41, and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:42; or The amino acid sequence of the HCDR1 is shown in SEQ ID NO:31, the amino acid sequence of the HCDR2 is shown in SEQ ID NO:45, the amino acid sequence of the HCDR3 is shown in SEQ ID NO:46, the amino acid sequence of the LCDR1 is shown in SEQ ID NO:47, the amino acid sequence of the LCDR2 is shown in SEQ ID NO:48 and the amino acid sequence of the LCDR3 is shown in SEQ ID NO:49; in, The amino acid sequences of HCDRs and LCDRs are according to the Kabat definition.

2. The antibody of claim 1, wherein the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 13, 19, 21, 22 or 43.

3. The antibody of claim 1, wherein the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 14, 20, 23 or 44.

4. The antibody according to any one of claims 1 to 3, wherein The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 13, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 14; The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 19, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 20; The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 21, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 20; The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 22, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 23; or The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:43, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:

44.

5. An antibody that binds to human IL-15, wherein the amino acid sequence of the heavy chain variable region of the antibody is at least 90% identical to any one of SEQ ID NOs: 13, 19, 21, 22 and 43, and the amino acid sequence of the light chain variable region of the antibody is at least 90% identical to any one of SEQ ID NOs: 14, 20, 23 and 44.

6. The antibody of any one of claims 1 to 5, wherein The antibody is a whole antibody, a Fab fragment, a F(ab')2 fragment or a single-chain Fv fragment (scFv); preferably, the antibody is a fully human antibody or a humanized antibody; and / or The antibody is a monoclonal antibody; and / or The antibody further comprises a heavy chain constant region selected from IgG1 subtype, IgG2 subtype or IgG4 subtype; preferably, the heavy chain constant region is IgG1 subtype; more preferably, the heavy chain constant region is IgG1m3 subtype; and / or The amino acids at positions 234, 235 and 331 of the Fc fragment are F, E and S respectively; and / or The amino acids at positions 252, 254 and 256 of the heavy chain constant region are Y, T and E, respectively; and / or The antibody further comprises a light chain constant region selected from a κ subtype or a λ subtype; preferably, the light chain constant region is a κ subtype; in, The amino acid positions of antibody constant regions are determined according to EU numbering.

7. The antibody of any one of claims 1 to 6, wherein The antibody binds to human IL-15 and / or monkey IL-15; and / or The antibody can inhibit the activity of IL-15, for example, inhibit the ability of IL-15 to induce secretory embryonic alkaline phosphatase (SEAP) secretion and / or inhibit the ability of IL-15 to induce NK92 cell proliferation.

8. A nucleic acid molecule encoding the antibody of any one of claims 1 to 7.

9. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 7 and a pharmaceutically acceptable excipient, diluent or carrier.

10. The pharmaceutical composition according to claim 9, which is used for preventing or treating IL-15-mediated diseases; preferably, the IL-15-mediated diseases are selected from: vitiligo, celiac disease, eosinophilic esophagitis and large granular lymphocytic leukemia.

11. Use of the antibody according to any one of claims 1 to 7 or the pharmaceutical composition according to claim 9 or 10 in the preparation of a medicament for preventing or treating an IL-15-mediated disease; preferably, the IL-15-mediated disease is selected from: vitiligo, celiac disease, eosinophilic esophagitis and large granular lymphocytic leukemia.

12. A method for preventing or treating an IL-15-mediated disease, comprising administering to an individual in need thereof the antibody of any one of claims 1 to 7, or the pharmaceutical composition of claim 9 or 10; preferably, the IL-15-mediated disease is selected from the group consisting of vitiligo, celiac disease, eosinophilic esophagitis and large granular lymphocytic leukemia.

Citation Information

Patent Citations

  • Recombinant system for expressing Fab fragment library

    CN117430696A

  • Antibodies to IL-15

    US10301384B2

  • Antigen binding molecules comprising a TNF family ligand trimer

    US20160200833A1

  • Human antibodies specific for interleukin 15 (IL-15)

    US7153507B2

  • Antibodies to IL-15

    CN106661106A